<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198441</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol Number: 100</org_study_id>
    <nct_id>NCT04198441</nct_id>
  </id_info>
  <brief_title>The Omeza Protocol for Chronic Ulcers</brief_title>
  <official_title>A Randomized, Multicenter, Open Label Study Comparing the Omeza® Products Bundle to Standard of Care for Chronic Venous Leg Ulcers and Chronic Diabetic Foot Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Omeza, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Omeza, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the Omeza® Products Bundle to standard of care (SOC) for in subjects&#xD;
      with chronic venous leg ulcers and subjects with diabetic foot ulcers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, multi-center, open-label study comparing the Omeza® Products Bundle&#xD;
      versus standard of care treatments for 2 different types of chronic ulcers (venous leg ulcers&#xD;
      and diabetic foot ulcers). The treatment period will be 12 weeks, with subjects coming into&#xD;
      the study site weekly for evaluations, photography and formal measurements of the target&#xD;
      wound, and dressing changes. There will be a total of 13 study site visits. The Screening&#xD;
      Visit (Day 0) will occur 1 week prior to randomization and will include routine labs and&#xD;
      vascular assessment to determine inclusion/exclusion of the potential subject from the study;&#xD;
      followed by weekly treatment visits (Week 1 through Week 11); randomization will occur at&#xD;
      Treatment Visit Week 1; the Treatment Visit Week 12/End of Study Visit will include end of&#xD;
      study labs. Target wounds will be photographed and measured, and vascular assessment will be&#xD;
      done at each of the 13 visits.&#xD;
&#xD;
      If the wound closes before Week 12, the subject will continue to come in for all the&#xD;
      remaining study visits until study completion. If the wound does not close by Week 12, the&#xD;
      subject will be immediately exited from the study and no further follow-up will occur as part&#xD;
      of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound Closure</measure>
    <time_frame>13 weeks</time_frame>
    <description>Percent wound closure from baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wound Closure Rate</measure>
    <time_frame>13 weeks</time_frame>
    <description>Rate of wound closure measured weekly</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Maximum Wound Closure</measure>
    <time_frame>1-13 weeks</time_frame>
    <description>Number of weeks to achieve complete wound closure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Venous Leg Ulcer</condition>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>Omeza Value-based Bundle Test</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The Omeza value-based bundle consists of lidocaine lavage, flowable collagen matrix and skin protectant products.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Wound Care Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard wound care control is saline wound wash and wet to dry dressing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Wound dressing</intervention_name>
    <description>Clean wound, fill wound, dress wound</description>
    <arm_group_label>Omeza Value-based Bundle Test</arm_group_label>
    <arm_group_label>Standard Wound Care Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female 21-80 years of age&#xD;
&#xD;
          2. Participated in the informed consent process and signed study specific informed&#xD;
             consent document&#xD;
&#xD;
          3. Willing and able to comply with study procedures, including study visits and study&#xD;
             dressing regimens&#xD;
&#xD;
          4. Confirmation of venous disease by non-invasive venous studies with either Doppler-&#xD;
             confirmed venous reflux or having ≥ 2 clinical characteristics of venous insufficiency&#xD;
             (varicose veins, lipodermatosclersosis, venous dermatitis, atrophie blanche, edema).&#xD;
             Biopsy done to exclude other skin conditions e.g. cancer on ulcers ≥ 6 months&#xD;
&#xD;
          5. HbA1c of ≤ 10%&#xD;
&#xD;
          6. Have a venous ulcer between the knee and ankle, at or above the malleolus&#xD;
&#xD;
          7. For VLU's: Target wound size ≥ 4 cm2 to ≤ 150 cm2 in area without exposed tendon,&#xD;
             muscle or bone For DFU's: Target wound size ≥ 0.25 cm2 to ≤ 150 cm2 post debridement&#xD;
             at Screening Visit and Treatment Visit Week 1/Randomization&#xD;
&#xD;
          8. Target wound duration of at least 3 months and less than or equal to 12 months as of&#xD;
             the date the subject signs consent for study&#xD;
&#xD;
          9. Containing yellow/white slough with or without fibrous/scar tissue and/or non- viable&#xD;
             tissue&#xD;
&#xD;
         10. Be willing and able (or have family member/friend willing and able) to apply required&#xD;
             dressing changes as well as the ability of the subject to tolerate limb compression&#xD;
             bandage&#xD;
&#xD;
         11. Ankle-Branchial Index (ABI) less than 0.80 or greater than 1.3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects with a BMI ≥ 65&#xD;
&#xD;
          2. Subject is medically unable to consent (due to head trauma, coma, etc.) or cognitively&#xD;
             impaired (due to being mentally challenged, having Alzheimer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew J Applewhite, MD,CWSP,FUHM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor University Medical Center's Comprehensive Wound Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Swain, DPM,CWSP</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Coast Cardiovascular Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert B McLafferty, MD,MBA,FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacob Reinkraut, DPM,FACFAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Michael's Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luba Lavrik</last_name>
    <phone>561-200-3344</phone>
    <phone_ext>4438</phone_ext>
    <email>LLavrik@PalmBeachCRO.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First Coast Cardiovascular Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Hudson</last_name>
      <phone>904-493-3333</phone>
      <email>mhudson@firstcoastcardio.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Michael's Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Fallon</last_name>
      <phone>973-877-2663</phone>
      <email>JFallon@primehealthcare.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University (OHSU)</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Louie</last_name>
      <phone>503-494-6238</phone>
      <email>louida@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor Scott &amp; White Comprehensive Wound Care Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Desirae Ransom, MS,CCRC</last_name>
      <phone>214-818-2526</phone>
      <email>Desirae.Ransom@BSWHealth.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>April 8, 2021</last_update_submitted>
  <last_update_submitted_qc>April 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

